MedTrace Logo

Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake

NCT01232946 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-08-07

Study results available
· View outcomes & findings →

Summary

27 Type 2 diabetic subjects (HbA1c 7.5 - 9.5%) currently treated with diet and exercise alone or with oral antidiabetic agents will be randomly assigned to one of three treatment groups: insulin detemir, liraglutide, or liraglutide plus detemir (9 subjects per group), on a background of metformin 2000 mg per day. After 3 months' treatment, PET measurements of myocardial fuel selection will take place, under fasting conditions in the morning following that day's treatment injection(s).

Conditions

Interventions

DRUG

liraglutide

1.8mg subcutaneous qd for 3 months

DRUG

insulin detemir

5units subcutaneous bid titrated to fasting glucose of \<130mg/dL for 3 months

DRUG

liraglutide plus insulin detemir

liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose \<130mg/dL for 3 months.

Sponsors & Collaborators

Principal Investigators

  • Kieren J Mather, MD · Indiana University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2017-09-08
Completion
2017-09-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01232946 on ClinicalTrials.gov